LAS VEGAS, April 14, 2017 /PRNewswire/ -- The International Society for CNS Drug Development (ISCDD) announced today thatRaymond Sanchez, M.D., Senior Vice President, Global Clinical Development at Otsuka Pharmaceutical Development & Commercialization (OPDC), has been elected as the Chairman of the Executive Committee for the ISCDD.
"For the past fifteen years, the ISCDD has played a significant role in shaping the present and future development of CNS therapies," said Dr. Sanchez. "I am committed to continue to help make strides with others in CNS endeavors and look forward to substantial progress over the next four years as we incorporate and leverage innovative approaches to development."
The International Society for CNS Drug Development (ISCDD) is a non-profit, independent leadership forum founded in 2002 to improve central nervous system drug development through collaboration amongst stakeholders including industry, academia, and government.
For more information, please contact:
Erica Moore ISCDD Secretariat O: 702-992-0784 M: 610-613-3524 email@example.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/raymond-sanchez-elected-chairman-of-iscdd-executive-committee-at-iscdd-2017-annual-meeting-300439814.html
Subscribe to our Free Newsletters!
Nocturnal polyuria refers to increased urine output during night, without an associated increase in ...
Nootropics are drugs or substances which improve cognition that are being increasingly used ...
Pterygium or Surfer's eye is described as a proliferative disorder of the ocular surface possibly ...View All